| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Didanosine (also known as 2′,3′-dideoxyinosine, ddI, DDI; trade names Videx and Videx EC) is a potent reverse transcriptase inhibitor with an IC50 of 0.49 μM. It is an antiretroviral drug used to treat HIV/AIDS in combination with other medications as part of highly active antiretroviral therapy (HAART). Didanosine is of the reverse transcriptase inhibitor class and is on the WHO World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
| ln Vitro |
Cellular enzymes transform didanosine into dideoxyadenosine triphosphate (dd-ATP), a potent antiviral metabolite with an intracellular half-life that ranges from 8 to 24 hours[1]. Didanosine exhibits antiretroviral action against HIV infection, with an IC50 value of 0.24–0.6 mg/L[3]. In IEC-6 cells, didanosine (5, 10, 50, and 100 ug/ml; 24 and 48 hours) does not significantly reduce cell proliferation[2].
|
|---|---|
| ln Vivo |
For seven days, mice given didanosine (100, 150 mg/kg; po) have shorter duodenal and jejunal villus[2].
|
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: IEC-6 cells Tested Concentrations: 5, 10, 50, 100 ug/ml Incubation Duration: 24, 48 h Experimental Results: Did not show any significant inhibition of cell proliferation at either 24 h or 48 h. Apoptosis Analysis[2] Cell Types: IEC-6 cells Tested Concentrations: 100 ug/ml Incubation Duration: 24 h Experimental Results: Induced apoptosis with the apoptosis rates of 4.7% to 7.4%. |
| Animal Protocol |
Animal/Disease Models: 30-40 g, male swiss mice[2]
Doses: 100, 150 mg/kg Route of Administration: Po; daily for 7 days Experimental Results: Caused significant reductions in duodenal and in jejunal villus length and Dramatically diminished ileal crypt depth. |
| References |
[1]. Munir N.Nassar, et al. Analytical profiles of drug substances and excipients. Journals & Books, 1993, 185-227.
[2]. Braga Neto MB, et al. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol. 2010 Aug 11;10:90. [3]. Caroline M. Perry, et al. Didanosine. Drugs, 1999, 58, 1099-1135. |
| Molecular Formula |
C10H12N4O3
|
|
|---|---|---|
| Molecular Weight |
236.23
|
|
| CAS # |
69655-05-6
|
|
| Related CAS # |
Didanosine-d2
|
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])C([H])([H])C([H])([H])[C@]1([H])N1C([H])=NC2C(N([H])C([H])=NC1=2)=O
|
|
| InChi Key |
BXZVVICBKDXVGW-NKWVEPMBSA-N
|
|
| InChi Code |
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s
|
|
| Chemical Name |
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2332 mL | 21.1658 mL | 42.3316 mL | |
| 5 mM | 0.8466 mL | 4.2332 mL | 8.4663 mL | |
| 10 mM | 0.4233 mL | 2.1166 mL | 4.2332 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA